COX-2 expression in pseudomyxoma peritonei

Zoran Gatalica, Brian W. Loggie

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

COX-2 expression was studied using an immunohistochemical method in 75 patients with pseudomyxoma peritonei (PMP). Twenty-five patients presented with disseminated peritoneal adenomucinosis (DPAM) and 50 with peritoneal mucinous carcinomatosis (PMCA). COX-2 was expressed in neoplastic mucinous epithelium of 30 cases (40%): 20 in PMCA (40%), 10 in DPAM (40%). Weak COX-2 expression was also noted in four of five patients with appendiceal mucinous neoplasms without peritoneal dissemination. In addition, COX-2 was detected in stromal, endothelial, inflammatory cells and reactive mesothelium. This preliminary information indicates a potential for the use of COX-2 inhibitors in patients with PMP.

Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalCancer Letters
Volume244
Issue number1
DOIs
StatePublished - Nov 28 2006

Fingerprint

Pseudomyxoma Peritonei
Appendiceal Neoplasms
Epithelium
Carcinoma
Cyclooxygenase 2 Inhibitors
Endothelial Cells

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

COX-2 expression in pseudomyxoma peritonei. / Gatalica, Zoran; Loggie, Brian W.

In: Cancer Letters, Vol. 244, No. 1, 28.11.2006, p. 86-90.

Research output: Contribution to journalArticle

Gatalica, Zoran ; Loggie, Brian W. / COX-2 expression in pseudomyxoma peritonei. In: Cancer Letters. 2006 ; Vol. 244, No. 1. pp. 86-90.
@article{fc779a2d018b46b5a0ff0a4fc1f28b2c,
title = "COX-2 expression in pseudomyxoma peritonei",
abstract = "COX-2 expression was studied using an immunohistochemical method in 75 patients with pseudomyxoma peritonei (PMP). Twenty-five patients presented with disseminated peritoneal adenomucinosis (DPAM) and 50 with peritoneal mucinous carcinomatosis (PMCA). COX-2 was expressed in neoplastic mucinous epithelium of 30 cases (40{\%}): 20 in PMCA (40{\%}), 10 in DPAM (40{\%}). Weak COX-2 expression was also noted in four of five patients with appendiceal mucinous neoplasms without peritoneal dissemination. In addition, COX-2 was detected in stromal, endothelial, inflammatory cells and reactive mesothelium. This preliminary information indicates a potential for the use of COX-2 inhibitors in patients with PMP.",
author = "Zoran Gatalica and Loggie, {Brian W.}",
year = "2006",
month = "11",
day = "28",
doi = "10.1016/j.canlet.2005.12.013",
language = "English",
volume = "244",
pages = "86--90",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - COX-2 expression in pseudomyxoma peritonei

AU - Gatalica, Zoran

AU - Loggie, Brian W.

PY - 2006/11/28

Y1 - 2006/11/28

N2 - COX-2 expression was studied using an immunohistochemical method in 75 patients with pseudomyxoma peritonei (PMP). Twenty-five patients presented with disseminated peritoneal adenomucinosis (DPAM) and 50 with peritoneal mucinous carcinomatosis (PMCA). COX-2 was expressed in neoplastic mucinous epithelium of 30 cases (40%): 20 in PMCA (40%), 10 in DPAM (40%). Weak COX-2 expression was also noted in four of five patients with appendiceal mucinous neoplasms without peritoneal dissemination. In addition, COX-2 was detected in stromal, endothelial, inflammatory cells and reactive mesothelium. This preliminary information indicates a potential for the use of COX-2 inhibitors in patients with PMP.

AB - COX-2 expression was studied using an immunohistochemical method in 75 patients with pseudomyxoma peritonei (PMP). Twenty-five patients presented with disseminated peritoneal adenomucinosis (DPAM) and 50 with peritoneal mucinous carcinomatosis (PMCA). COX-2 was expressed in neoplastic mucinous epithelium of 30 cases (40%): 20 in PMCA (40%), 10 in DPAM (40%). Weak COX-2 expression was also noted in four of five patients with appendiceal mucinous neoplasms without peritoneal dissemination. In addition, COX-2 was detected in stromal, endothelial, inflammatory cells and reactive mesothelium. This preliminary information indicates a potential for the use of COX-2 inhibitors in patients with PMP.

UR - http://www.scopus.com/inward/record.url?scp=33749261636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749261636&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2005.12.013

DO - 10.1016/j.canlet.2005.12.013

M3 - Article

C2 - 16427185

AN - SCOPUS:33749261636

VL - 244

SP - 86

EP - 90

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -